{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:44:21Z","timestamp":1792817061710,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"\n Purpose of review<\/jats:title>\n Sarcoidosis is a systemic disease characterized by noncaseating granulomatous inflammation of multiple organ systems. Pulmonary, cardiac, and neurologic involvements have the worst prognosis. Current recommendations for the therapeutic management and follow-up of sarcoidosis involving these critical organs will be reviewed.<\/jats:p>\n <\/jats:sec>\n \n Recent findings<\/jats:title>\n In those sarcoidosis patients requiring immunosuppressive therapy, corticosteroids are used first at varying doses depending on the presenting manifestation. Patients with symptomatic pulmonary, cardiac, or neurologic involvement will be maintained on corticosteroids for at least a year. Many require a second immunosuppressive agent with methotrexate used most commonly. Anti-tumor necrosis factor agents, especially infliximab, are effective and recommendations for their use have been proposed.<\/jats:p>\n <\/jats:sec>\n \n Summary<\/jats:title>\n Evidence-based treatment guidelines do not exist for most sarcoidosis clinical manifestations. Therefore, clinical care of these patients must rely on expert opinion. Patients are best served by a multidisciplinary approach to their care. Future research to identify environmental triggers, genetic associations, biomarkers for treatment response, and where to position new steroid-sparing immunosuppressive agents is warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/bor.0000000000000489","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T13:16:01Z","timestamp":1517490961000},"page":"243-248","source":"Crossref","is-referenced-by-count":29,"title":["Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations"],"prefix":"10.1097","volume":"30","author":[{"given":"Sterling G.","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","first-page":"736","article-title":"Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.berh.2016.07.001","article-title":"Sarcoidosis: Rheumatology perspective","volume":"30","author":"Yee","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0037-1604032","article-title":"Current medical therapy for sarcoidosis","volume":"38","author":"Valeyre","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"R5-20230828","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/1744666X.2016.1175301","article-title":"Biologic therapies in the treatment of sarcoidosis","volume":"12","author":"Saketkoo","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0037-1603766","article-title":"Pulmonary sarcoidosis","volume":"38","author":"Bonifazi","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1586\/17476348.2016.1164602","article-title":"Clinical management of pulmonary sarcoidosis","volume":"10","author":"Zhou","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"R10-20230828","first-page":"46","article-title":"Efficacy results of a 52 week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"1700465","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis","volume":"68","author":"Birnie","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/ehjci\/jex146","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology","volume":"18","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"e005001","DOI":"10.1161\/CIRCIMAGING.116.005001","article-title":"Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systemic review and meta-analysis","volume":"9","author":"Hulten","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0037-1602381","article-title":"Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment","volume":"38","author":"Sayah","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0037-1604165","article-title":"Neurosarcoidosis","volume":"38","author":"Culver","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.rdc.2017.06.008","article-title":"Neurosarcoidosis","volume":"43","author":"Ungprasert","year":"2017","journal-title":"Rheum Dis Clin N Am"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00415-016-8336-4","article-title":"Neurosarcoidosis: a clinical approach to diagnosis and management","volume":"264","author":"Ibitoye","year":"2017","journal-title":"J Neurol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil in the prevention of relapses in neurosarcoidosis","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multiinstitutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J Neurol"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","article-title":"Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement","volume":"55","author":"Sharma","year":"1998","journal-title":"Arch Neurol"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1097\/01.COC.0000077933.69101.5D","article-title":"Role of radiotherapy in the treatment of neurosarcoidosis","volume":"26","author":"Menninger","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.acvd.2016.12.014","article-title":"Cardiac sarcoidosis: diagnosis, therapeutic management, and prognostic factors","volume":"110","author":"Chapelon-Abric","year":"2017","journal-title":"Archives Cardiovasc Dis"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment, and outcome in neurosarcoidosis: systemic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201805000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:06:35Z","timestamp":1693184795000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201805000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000489","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}